Imperial College London
Alternate

Jeff Imai-Eaton

Faculty of Medicine, School of Public Health

Senior Research Fellow
 
 
 
//

Contact

 

jeffrey.eaton

 
 
//

Location

 

UG7Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Eaton:2017:10.1016/S2352-3018(17)30148-0,
author = {Eaton, JW and Hargreaves, J},
doi = {10.1016/S2352-3018(17)30148-0},
journal = {Lancet HIV},
pages = {e429--e430},
title = {How will we get there? How will we know?},
url = {http://dx.doi.org/10.1016/S2352-3018(17)30148-0},
volume = {4},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Ending AIDS by 2030 is a monumental challenge. Tracking progress as incidence reaches lower levels could be just as challenging. In The Lancet HIV Sabin Nsanzimana and colleagues report progress and highlight the challenges that lie ahead on both fronts. The Rwanda HIV Incidence Survey enumerated a nationally representative sample of 13 728 HIV-negative adults in 2013, and followed up a remarkable 92% of participants 1 year later. The investigators detected 35 HIV seroconversions at follow-up. Two findings are especially noteworthy.
AU  - Eaton,JW
AU  - Hargreaves,J
DO  - 10.1016/S2352-3018(17)30148-0
EP  - 430
PY  - 2017///
SN  - 2405-4704
SP  - 429
TI  - How will we get there? How will we know?
T2  - Lancet HIV
UR  - http://dx.doi.org/10.1016/S2352-3018(17)30148-0
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411617100005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/58359
VL  - 4
ER  -
Download